Watch: 23andMe CEO addresses FDA setback

On November 22, the FDA sent 23andMe a letter saying that the company did not have approval to market its product as a medical device. The company sells DNA Spit Kits for $99, which are then mailed back to 23andMe and used to sequence part of a customer’s genome. 23andMe has since stopped marketing the kits and yesterday announced it would no longer provide heath data to new customers, while the company undergoes a regulatory review process.

As company co-founder and CEO Anne Wojcicki says in the above interview with Fortune senior editor-at-large Patricia Sellers—the first and so far only interview in which she addresses the FDA’s charges—”We have to solve the problem.”